Company Overview
Snapshot
Founded in March 2018 by Ze’ev Ronai, Eyal Gottlieb, and Eytan Ruppin, Pangea Biomed operates with 11–50 employees. The company has raised $12 million across two funding rounds from investors including NFX Capital. In December 2022, Pangea Biomed secured additional seed funding to advance its multi-cancer response predictor technology.
Business overview
Pangea Biomed develops ENLIGHT, an advanced pan-cancer, pan-therapy response predictor that leverages machine learning, artificial intelligence, and deep RNA analysis to personalize cancer care. The company's technology maps tumor molecular signatures to enable dynamic and adaptive treatment strategies, proving effective even when clinical data is unavailable. Pangea Biomed also offers EnlightDP, a response prediction technology based on digital H&E slide image analysis using its proprietary RNA expression imputation platform. The company aims to enhance precision oncology for patients, improve drug development processes, and empower oncologists, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Pharma & Medical Biotechnology.
Strategic signal
In December 2022, Pangea Biomed secured additional seed funding, signaling continued investor confidence in its multi-cancer response predictor technology. This capital infusion supports the ongoing development and scaling of ENLIGHT, reinforcing the company's position in advancing precision oncology and personalized cancer treatment through AI and deep RNA analysis.
Log in to access full profile ›Company Intelligence Q&A
- What is Pangea Biomed's core technology?
- Pangea Biomed's core technology is ENLIGHT, an advanced pan-cancer, pan-therapy response predictor that utilizes machine learning, artificial intelligence, and deep RNA analysis to personalize cancer care by mapping tumor molecular signatures.
- When was Pangea Biomed founded?
- Pangea Biomed was founded in March 2018 by Ze’ev Ronai, Eyal Gottlieb, and Eytan Ruppin.
- How much capital has Pangea Biomed raised to date?
- Pangea Biomed has raised a total of $12 million across two funding rounds.
- Which investors participated in Pangea Biomed's funding rounds?
- Pangea Biomed has received funding from investors including NFX Capital.
- What was a significant recent development for Pangea Biomed?
- In December 2022, Pangea Biomed added $5 million in additional funding to further develop its multi-cancer response predictor technology.